| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200509-1518OC |
| P698 | PubMed publication ID | 16415274 |
| P50 | author | Dmitri V Pechkovsky | Q37829293 |
| Joachim Müller-Quernheim | Q47008767 | ||
| Antje Prasse | Q47008769 | ||
| Torsten Goldmann | Q50033276 | ||
| P2093 | author name string | Galen B Toews | |
| Antje Prasse | |||
| Gernot Zissel | |||
| Wolfgang Jungraithmayr | |||
| Ekkehard Vollmer | |||
| Florian Kollert | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pulmonary fibrosis | Q32446 |
| P304 | page(s) | 781-792 | |
| P577 | publication date | 2006-01-13 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. | |
| P478 | volume | 173 |
| Q36579788 | A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis |
| Q37012557 | Accelerated development of pulmonary fibrosis via Cu,Zn-superoxide dismutase-induced alternative activation of macrophages |
| Q37098588 | Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis |
| Q35598027 | Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines |
| Q43179219 | Acute Exacerbation in Interstitial Lung Disease |
| Q52642363 | Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? |
| Q38008342 | Acute lung injury: how macrophages orchestrate resolution of inflammation and tissue repair |
| Q36673494 | Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity |
| Q38814035 | Advances in understanding the immunopathology of sarcoidosis and implications on therapy. |
| Q41884288 | Age-Dependent Susceptibility to Pulmonary Fibrosis Is Associated with NLRP3 Inflammasome Activation |
| Q36192785 | Alternatively Activated (M2) Macrophage Phenotype Is Inducible by Endothelin-1 in Cultured Human Macrophages |
| Q26823579 | Alternatively activated macrophages and airway disease |
| Q64256304 | Alveolar-Capillary Membrane-Related Pulmonary Cells as a Target in Endotoxin-Induced Acute Lung Injury |
| Q34938538 | An agent-based model of inflammation and fibrosis following particulate exposure in the lung |
| Q33765684 | Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients |
| Q35628723 | Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. |
| Q40749683 | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas |
| Q49048144 | Barrier-tissue macrophages: functional adaptation to environmental challenges |
| Q38572850 | Bidirectional crosstalk via IL-6, PGE2 and PGD2 between murine myofibroblasts and alternatively activated macrophages enhances anti-inflammatory phenotype in both cells |
| Q91777189 | Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature |
| Q98224788 | Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects |
| Q39206288 | Blood Biomarkers in Idiopathic Pulmonary Fibrosis |
| Q44583364 | Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. |
| Q34562135 | CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential |
| Q34951532 | CCL18 exhibits a regulatory role through inhibition of receptor and glycosaminoglycan binding |
| Q48027626 | CCL18 production is decreased in alveolar macrophages from cigarette smokers |
| Q36149014 | CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells. |
| Q41382922 | Cell plasticity in wound healing: paracrine factors of M1/ M2 polarized macrophages influence the phenotypical state of dermal fibroblasts |
| Q58758969 | Chemokine-Induced Macrophage Polarization in Inflammatory Conditions |
| Q28384802 | Chitotriosidase in the Pathogenesis of Inflammation, Interstitial Lung Diseases and COPD |
| Q35035253 | Chlamydia pneumoniae infection in mice induces chronic lung inflammation, iBALT formation, and fibrosis |
| Q41688556 | Chromofungin Ameliorates the Progression of Colitis by Regulating Alternatively Activated Macrophages. |
| Q38044387 | Circulating biomarkers of interstitial lung disease in systemic sclerosis |
| Q42154997 | Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. |
| Q36541723 | Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis |
| Q37768235 | Clinical use of biomarkers of survival in pulmonary fibrosis |
| Q35916001 | Complex regulation of pulmonary inflammation and fibrosis by CCL18 |
| Q35855163 | Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice |
| Q48259566 | Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis |
| Q46785228 | Current development and usefulness of biomarkers for Gaucher disease follow up |
| Q38156227 | Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development |
| Q42113962 | Cytokines in chronic respiratory diseases |
| Q92117796 | D-4F, an apolipoprotein A-I mimetic, suppresses IL-4 induced macrophage alternative activation and pro-fibrotic TGF-β1 expression |
| Q33649048 | Defective efferocytosis by alveolar macrophages in IPF patients |
| Q36608217 | Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension |
| Q92670173 | Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns |
| Q28385959 | Epithelial neoplasia coincides with exacerbated injury and fibrotic response in the lungs of Gprc5a-knockout mice following silica exposure |
| Q82331355 | Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis |
| Q37351580 | Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome |
| Q37164171 | Essential role of osteopontin in smoking-related interstitial lung diseases |
| Q58773988 | Evaluation of Tc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis |
| Q37156395 | Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF |
| Q99634847 | Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review |
| Q38290398 | Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis |
| Q38570322 | Functional autoantibodies in systemic sclerosis |
| Q39804171 | GRP78 and CHOP modulate macrophage apoptosis and the development of bleomycin-induced pulmonary fibrosis. |
| Q47233198 | Genetic, Immunologic, and Environmental Basis of Sarcoidosis |
| Q47712616 | High-Risk Sarcoidosis. Current Concepts and Research Imperatives |
| Q26852800 | Host responses in tissue repair and fibrosis |
| Q39308555 | Human Lung Mononuclear Phagocytes in Health and Disease. |
| Q34290773 | Human conjunctival transcriptome analysis reveals the prominence of innate defense in Chlamydia trachomatis infection |
| Q37071862 | IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis |
| Q50232084 | Identification of transforming growth factor beta1-driven genetic programs of acute lung fibrosis |
| Q47901631 | Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies |
| Q37152292 | Idiopathic pulmonary fibrosis: the need for early diagnosis |
| Q38826634 | Immune Mechanisms in Pulmonary Fibrosis |
| Q35708762 | Immune response to Propionibacterium acnes in patients with sarcoidosis--in vivo and in vitro |
| Q41727507 | Immunoproteasome dysfunction augments alternative polarization of alveolar macrophages |
| Q35223657 | Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis |
| Q40836532 | Impairment of Immunoproteasome Function by Cigarette Smoke and in Chronic Obstructive Pulmonary Disease |
| Q94563744 | Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease |
| Q35634156 | Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps. |
| Q35649461 | Infectious disease, the innate immune response, and fibrosis |
| Q89497679 | Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment |
| Q91612368 | Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide |
| Q35106452 | Integrating mechanisms of pulmonary fibrosis |
| Q38266881 | Interleukin-12 family cytokines and sarcoidosis |
| Q33722773 | Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages |
| Q39080263 | Interplay of extracellular matrix and leukocytes in lung inflammation. |
| Q64055637 | Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF |
| Q38370676 | Involvement of fibrocytes in asthma and clinical implications |
| Q44729879 | In vitro model to study the biomaterial-dependent reaction of macrophages in an inflammatory environment. |
| Q42366226 | Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)? |
| Q26777122 | Leukocytes: The Double-Edged Sword in Fibrosis |
| Q35054029 | Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation |
| Q99574032 | M2 macrophage markers in type 2 diabetes |
| Q34756244 | M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis |
| Q39565014 | Macrophage activation and skeletal muscle healing following traumatic injury |
| Q34973462 | Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis |
| Q46469503 | Macrophage depletion reduces cell proliferation and extracellular matrix accumulation but increases the ultimate tensile strength of injured Achilles tendons |
| Q36692041 | Macrophage heterogeneity in respiratory diseases |
| Q42099223 | Macrophage-derived biomarkers of idiopathic pulmonary fibrosis |
| Q33760755 | Macrophages produce TGF-beta-induced (beta-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts |
| Q88089775 | Macrophages, Wound Healing, and Fibrosis: Recent Insights |
| Q58761750 | Macrophages: friend or foe in idiopathic pulmonary fibrosis? |
| Q34076279 | Macrophages: master regulators of inflammation and fibrosis |
| Q28070094 | Mechanisms of the alternative activation of macrophages and non-coding RNAs in the development of radiation-induced lung fibrosis |
| Q31158830 | Meta-analytic support vector machine for integrating multiple omics data |
| Q40491886 | MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells. |
| Q41855099 | MicroRNA let-7c regulates macrophage polarization. |
| Q36237168 | Molecular and cellular mechanisms of pulmonary fibrosis |
| Q27025340 | Molecular biomarkers in idiopathic pulmonary fibrosis |
| Q26864836 | Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers |
| Q58004304 | Morphological and molecular markers in idiopathic pulmonary fibrosis |
| Q90080269 | Mucins as a New Frontier in Pulmonary Fibrosis |
| Q38130161 | New approaches to modulating idiopathic pulmonary fibrosis |
| Q34128472 | No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis |
| Q90260610 | Oxidative Stress in Pulmonary Fibrosis |
| Q41525696 | P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. |
| Q42370082 | PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent |
| Q54570243 | Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages. |
| Q43631328 | Paired immunoglobulin-like receptor-B inhibits pulmonary fibrosis by suppressing profibrogenic properties of alveolar macrophages |
| Q34022544 | Pathway-focused arrays reveal increased matrix metalloproteinase-7 (matrilysin) transcription in trachomatous trichiasis. |
| Q27000707 | Peripheral blood biomarkers in idiopathic pulmonary fibrosis |
| Q46920626 | Phenotyping sarcoidosis from a pulmonary perspective |
| Q54938157 | Phytochemicals as modulators of M1-M2 macrophages in inflammation. |
| Q51359224 | Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. |
| Q37594827 | Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis |
| Q57173045 | Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials |
| Q55509399 | Prominent Levels of the Profibrotic Chemokine CCL18 during Peritonitis: In Vitro Downregulation by Vitamin D Receptor Agonists. |
| Q28388425 | Pulmonary fibrosis: pathogenesis, etiology and regulation |
| Q35963236 | Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia |
| Q36232198 | Regulation of inflammation by interleukin-4: a review of "alternatives" |
| Q38115809 | Role of CCL18 in asthma and lung immunity. |
| Q34199947 | Sarcoidosis--scientific progress and clinical challenges |
| Q27006756 | Sarcoidosis: Immunopathogenesis and Immunological Markers |
| Q36757477 | Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma. |
| Q41020098 | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
| Q28748540 | Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages |
| Q28728826 | Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas |
| Q35049443 | Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments |
| Q39079920 | Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease |
| Q35164366 | Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin-degrading enzyme |
| Q36682162 | Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways |
| Q36348476 | Sustained low peritoneal effluent CCL18 levels are associated with preservation of peritoneal membrane function in peritoneal dialysis. |
| Q36465254 | T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis. |
| Q28387228 | Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis |
| Q36659528 | The Metabolic Prospective and Redox Regulation of Macrophage Polarization |
| Q42694416 | The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis |
| Q28070412 | The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung |
| Q36488735 | The alveolar epithelium determines susceptibility to lung fibrosis in Hermansky-Pudlak syndrome |
| Q24606039 | The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum |
| Q41862598 | The clinical and immunologic features of pulmonary fibrosis in sarcoidosis |
| Q55046775 | The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung. |
| Q64044987 | The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease |
| Q85166712 | The impact of gas exchange measurement during exercise in pulmonary sarcoidosis |
| Q35149385 | The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages |
| Q41056057 | The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. |
| Q38024820 | The role of macrophages in healing the wounded lung |
| Q64882374 | Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. |
| Q90628690 | Transcriptional regulatory model of fibrosis progression in the human lung |
| Q33799607 | Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages |
| Q35872012 | Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro |
| Q38134341 | Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. |
| Q36769703 | Update in diffuse parenchymal lung disease 2006. |
| Q85773001 | Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers |
| Q33703730 | Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine) |
| Q51362710 | YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia. |
| Q37622424 | mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis |
| Q36145947 | miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program |
Search more.